普罗布考对肾病综合征患者高脂血症的影响。

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.

作者信息

Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S

机构信息

Second Department of Internal Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.

出版信息

Nephron. 1987;47(4):280-3. doi: 10.1159/000184524.

DOI:10.1159/000184524

PMID:3696330

Abstract

We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome. Twelve patients with long-standing nephrotic syndrome received 500 mg of probucol daily for 12 weeks. Serum total cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol were significantly lowered with probucol treatment. There were no differences in urine protein, serum total protein, serum albumin and renal function before and after probucol treatment. No drug-related side effects were observed during our study. These results indicated that probucol was effective against hyperlipidemia and free from side effects in patients with persistent nephrotic syndrome. The use of probucol is therefore suggested to be advisable when antihyperlipidemic treatment is required in some subgroups of nephrotic syndrome.

摘要

我们评估了抗高脂血症药物普罗布考对肾病综合征患者高脂血症的影响。12例长期患有肾病综合征的患者每天服用500毫克普罗布考，持续12周。普罗布考治疗后，血清总胆固醇、甘油三酯、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇显著降低。普罗布考治疗前后尿蛋白、血清总蛋白、血清白蛋白和肾功能无差异。在我们的研究中未观察到与药物相关的副作用。这些结果表明，普罗布考对持续性肾病综合征患者的高脂血症有效且无副作用。因此，建议在肾病综合征的某些亚组需要进行抗高脂血症治疗时，使用普罗布考是可取的。